Novartis Cements Chiron Buy With Increased Bid

Chiron shareholders have agreed to vote in favor of the takeover at $48 per share, up from $45 per share deal Chiron accepted in October.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet